💣New Bombshell Myocarditis Study Out Of UK Reveals Sobering Effects Of mRNA COVID-19 Vaccines
everything you need to know
On December 14th, 2021 Nature Medicine released a study based on a broad population data set analyzed by researchers at Oxford examining the risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination and infection1. Interestingly, the literature revealed some eye opening information about myocarditis that will be discussed in this publication. Having said that, today you will learn 3 things:
First, you will learn a brief history of COVID-19 vaccine rollouts
Second, you will learn the pertinent details of this study like who experienced myocarditis, length of hospital stay associated with injury, and names of vaccine manufacturers involved
Third, you will learn what could be done in the USA to reduce the occurrence of vaccine induced myocarditis
📚First, some history
What brought things to this point? In other words, why this study examining adverse events following COVID-19 vaccination? To fully understand, you will need to hear a story first.
Early on amidst the pandemic in mid December of 2020, Pfizer was granted emergency use authorization for their mRNA vaccine against the SARS-CoV-2 virus in the UK. Said differently, Pfizer was afforded the ability by the FDA and WHO to deliver their COVID-19 vaccine to the general public for administration by healthcare professionals. It wasn’t long until many others followed suit: Moderna (April 2021), AstraZeneca (January 2021) etc. By September of 2021 nearly 6.3 billion doses had been administered around the world. As the months went by, adverse events after vaccination began being reported that were not seen in the original clinical trials.
By November 2021, the self reporting system VAERS (Vaccine Adverse Event Reporting System) revealed 1,783 reports of myocarditis and pericarditis from individuals between the ages of 12-30 that received Pfizer and Moderna’s mRNA vaccine2. By early July 2021, the EMA (European Medicines Agency) had 283 reports of myocarditis and pericarditis after 177 millions doses of Pfizer were administered, and of course 9 cases of myocarditis and 19 cases of pericarditis linked to Moderna 3. Simultaneously, Israel inoculated 5 million people with Pfizer (BNT162b2), and by May of 2021 275 cases of myocarditis were reported4.
So let’s examine the question again, why all of a sudden the interest in COVID-19 vaccine side effects? The answer, because initial vaccine clinical trials conducted by Pfizer, Moderna, and AstraZeneca revealed ⚠️NO CASES OF MYOCARDITIS OR PERICARDITIS⚠️. Conversely, when Pfizer, Moderna, and AstraZeneca’s vaccines were administered to the masses, individuals began experiencing side effects. That is bad because initial vaccine clinical trials are done to gauge the safety and efficacy of a drug/treatment for the general public. After all, if clinical trials are not accurate, people will get hurt. So, something must have went wrong, right?
Here is the problem. You see, the Moderna5, Pfizer6 , and AstraZeneca’s7 phase 3 clinical trials were very under powered. Said differently, they didn’t contain enough participants to account for rare side effects like myocarditis and pericarditis that are seen on average every 1/3000 - 1/8000 depending on extrapolation of data. To be more specific, in this case, extrapolations are calculations made in lieu of adequate data. Unfortunately, extrapolations are only as good as the data available. So, trying to quantify side effects based on already underpowered studies would be like trying to draw blood from a stone. What’s isn’t there, just isn’t there no matter what you do. Just so we’re clear, there should have been hundreds of thousands of participants in the initial clinical trials, NOT TENS OF THOUSANDS. Regardless of the speculative severity of COVID-19 at that time, it was not acceptable to do science differently from what is evidence based. If anything, we rely on tried and true measures to produce the best results, especially during a time so chaotic. Unfortunately, as certain safety steps were omitted, there are now people being harmed. Look at the figures below.
Moderna’s phase 3 clinical trail only contained approximately 30,000 individuals
Pfizer’s phase 3 clinical trail only contained approximately 43,000 individuals
AstraZeneca’s phase 3 clinical trail only contained approximately 29,000 individuals
🔔 THE TAKEAWAY
It seems that initial clinical trials for Moderna, Pfizer, and AstraZeneca being so underpowered created a blind spot. As a consequence, myocarditis was not seen during initial testing, but was experienced by the general population after mass vaccination. That is because the number of people inoculated worldwide is larger than the number of people studied in the clinical trials.
💡Second, examination of the study
QUICK SUMMARY: This case-series study out of Oxford examined the data of both males and females 16 years of age or older living in the UK who were recipients of COVID-19 adenovirus AstraZeneca (chAdOx1, n=20,615,911), mRNA Pfizer (BNT162b2, n=16,993,389), and mRNA Moderna (1273, n=1,006,191) vaccines, or who were SARS-CoV-2 positive between December 1st 2020 and August 24th 2021. The intent, to measure the rate of hospitalization or death from myocarditis, pericarditis, and cardiac arrhythmias after inoculation and COVID-19 infection in the 1-28 days following vaccination or positive RT-PCR test. To make this easier I will list the results below in bullet points and pictures. After that, you will read a brief assessment summarizing the findings.
*The number of participants that received each vaccine are indicated as “n”.
Total of 38,615,491 individuals
n= 1,006,191 vaccinated with Moderna (mRNA-1273)
n= 16,993,389 vaccinated with Pfizer (BNT162b2)
n= 20,615,911 vaccinated with AstraZeneca (ChAdOx1)
Amongst those who received 1 dose, 3,028,867 also had a positive test, of which 2,315,669 tested positive BEFORE vaccination; while 713,198 subsequently tested positive AFTER first dose, and 298,315 tested positive AFTER second dose
All individuals were followed for 28 days following receipt of primary series (dose 1 and 2 of Pfizer/Moderna, 1 dose AstraZeneca)
1,615 hospital admission for myocarditis
Average hospital stay for myocarditis admission was 3 days
114 deaths from vaccine induced myocarditis
📣 Some other pertinent information from the study not about myocarditis
1,574 hospital admissions for pericarditis
31 deaths from vaccine induced pericarditis
385,508 hospital admission for cardiac arrhythmias (irregular heart beat- too fast, too slow)
7,795 deaths from cardiac arrhythmias😳
Below are graphs detailing the occurrence of myocarditis overall, myocarditis in people 40 and younger, pericarditis, and cardiac arrhythmias post vaccination. I’d like to draw your attention to the first graph. The red bar indicates the event per million experienced (myocarditis overall) from COVID-19 infection. Moving to the highest bar on the second graph, you can see in people aged 40 and under, the risk of myocarditis is overwhelmingly higher from 2nd dose Moderna (orange bar) compared to simply getting COVID-19 infection (red bar next to orange bar on same graph). It is important to note, as mentioned in my previous publication, the risk of myocarditis is substantially higher in males 40 and under8. What’s interesting here is that, the 2nd graph below accounts for both males and females 40 and under. All and all, if the graph was reflective of ONLY MALES 40 and under, the orange bar would be much higher. Such a reflection suggests that males 40 and under experience much higher rates of myocarditis after vaccination with Moderna than any another other group.
🔔 THE TAKEAWAY
It seems individuals 40 and under (predominantly males) experience a higher rate of myocarditis after the 2nd dose of Moderna (mRNA-1273) and to a lesser degree Pfizer (BNT162b2) compared to others. Finally, next to no inflammatory heart conditions were seen after administration of AstraZeneca (ChAdOx1).
✅ What can be done to reduce the occurrence of vaccine induced myocarditis
In light of all the evidence, 3 things should be done IN THE UK AND USA to reduce vaccine induced myocarditis in people age 40 and under. They will be listed below in bullet points👇🏻
Individuals under 40 (mainly males) should get Pfizer instead of Moderna
Individuals under 40 (mainly males) should have doses from primary series spread apart 3 months or more if they do receive Moderna
Considering that many individuals 40 and under are healthy and have a low risk of experiencing serious side effects from COVID-19 infection, boosters should be selectively given. Not simply given to all males 40 and under
We need to look at what other nations are doing
➡️ As people under 40 (mainly males) are at higher risk for myocarditis after vaccination with Moderna, they should receive Pfizer instead. That is because the risk of myocarditis, pericarditis, and arrhythmias associated with the Pfizer vaccine is much lower. Moreover, politicians and public health officials need to stop using broad mandates, and public health policies with no give, as one size clearly doesn’t fit all.
➡️ Historically, when vaccines doses are spread out, less side effects and greater immunity seem to correlate9. To give you a recent example, researchers at at University of Birmingham found that giving a 2nd dose of Pfizer at 3 months instead of 3 weeks increased neutralizing antibodies 3.5 fold10. In light of that fact, spacing out doses could ameliorate side effects while also increasing immunity. This is something our public health officials, and politicians need to consider.
➡️ If you’re young and healthy you don’t necessarily need a booster. Most certainly not Moderna if you are a male under the age of 40. As a matter of fact, the harms will likely outweigh the benefits. Click here to read my previous publication on this.
➡️ Other countries are not taking the same one size fits all approach to vaccination like public health officials from the USA, and many parts of the UK are. That is because those public health officials and politicians understand the science. That is, males under the age of 40 seem to experience a higher rate of myocarditis after their second dose of Moderna. So, Moderna isn’t advised for all people. With that said, here is what other countries are doing:
🔔 THE TAKEAWAY
Public health policy in the USA and UK need to change fast. As a side note, if you listen to the mainstream media enough they’ll have you believing myocarditis is a mild symptom. Let me be clear, by definition, symptoms requiring hospitalization are defined as severe. What’s more, the average mortality rate of non-fulminant myocarditis is nearly 56% which is experienced within 3-10 years. Sadly, that is a consequence of the likely heart failure that develops after the acute phase of myocarditis has resolved. See picture below 👇🏻
All things considered, it is clear that individuals under 40 are at a high risk of experiencing vaccine induced myocarditis. The good news is, there are ways to deal with this. More specifically, increasing the time between the first and second dose, not giving boosters to all healthy individuals under 40, pausing Moderna for many under 30, and seeking the guidance of other countries. All of that makes for better public health policy and positive health outcomes. To finish, I will leave you with the words of a wise man, “Health care is vital to all of us some of the time, but public health is vital to all of us all of the time”. - C. Everett Koop